Skip to main content

Candel Therapeutics, Inc 8-K, filed Nov 12, 2026

Candel Therapeutics, Inc. (CADL)

8-K 2026-11-12 For: 2026-11-12
View Original
Added on November 13, 2026

About this 8-K

Candel Therapeutics, Inc filed this 8-K on November 12, 2026.

Candel Therapeutics plans to submit aglatimagene’s prostate cancer BLA in the middle of 2027 pending FDA dialogue, while $203.1 million in cash is expected to fund operations into Q2 2028. Third-quarter 2026 net loss widened to $21.9 million from $11.3 million. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits